Phase 2Phase 3RegistrationApproved in 2017 Fremanezumab (anti CGRP) Post-Traumatic Headache Fasinumab2 Chronic lower back pain Laquinimod Multiple sclerosis(progressive forms) Laquinimod Huntington disease Pridopidine Huntington disease Fremanezumab (anti CGRP) Cluster Headache Fasinumab2 Osteoarthritis pain Austedo® (SD-809)6 Tourette syndrome (U.S.) Reslizumab SC1 Asthma ProAir e-Respiclick® E-connectivity (U.S) Fremanezumab (anti CGRP) Chronic migraine Fremanezumab (anti CGRP) Episodic migraine Azilect ® Parkinson’s disease (Japan) ProAir e-Respiclick® E-connectivity (U.S) CT-P103 Biosimilar (Rituxan® U.S.) CT-P63 Biosimilar (Herceptin® U.S.) BENDEKA® CLL and NHL (Growth Markets) Trisonex ® for Acute Promyelocytic Leukemia (U.S.) Vantrela ® ER Pain (U.S.) Austedo ® Huntington disease (U.S.) Austedo ® Tardive dyskinesia(U.S.) ArmonAir ® RespiClick ® Asthma (U.S.) AirDuo ® RespiClick® Asthma (U.S.) QVAR® ( BAI) Asthma(U.S.) Reslizumab1 IV Asthma (selective Growth Markets)